161 related articles for article (PubMed ID: 36261902)
21. Jak Inhibitors Reverse Vitiligo in Mice but Do Not Deplete Skin Resident Memory T Cells.
Azzolino V; Zapata L; Garg M; Gjoni M; Riding RL; Strassner JP; Richmond JM; Harris JE
J Invest Dermatol; 2021 Jan; 141(1):182-184.e1. PubMed ID: 32464150
[No Abstract] [Full Text] [Related]
22. Jak inhibitors in vitiligo: a meta analysis.
Huang X; Ding X
Chin Med J (Engl); 2023 Dec; 136(23):2897-2898. PubMed ID: 37027285
[No Abstract] [Full Text] [Related]
23. Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis.
Phan K; Phan S; Shumack S; Gupta M
J Dermatolog Treat; 2022 Feb; 33(1):173-177. PubMed ID: 32096671
[TBL] [Abstract][Full Text] [Related]
24. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
25. Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors.
Cunningham KN; Rosmarin D
Am J Clin Dermatol; 2023 Mar; 24(2):165-186. PubMed ID: 36715849
[TBL] [Abstract][Full Text] [Related]
26. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B.
Joshipura D; Alomran A; Zancanaro P; Rosmarin D
J Am Acad Dermatol; 2018 Jun; 78(6):1205-1207.e1. PubMed ID: 29438765
[No Abstract] [Full Text] [Related]
27. JAK inhibitors in the treatment of atopic dermatitis.
Chovatiya R; Paller AS
J Allergy Clin Immunol; 2021 Oct; 148(4):927-940. PubMed ID: 34437922
[TBL] [Abstract][Full Text] [Related]
28. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo.
Rodríguez-Martín M; García Bustínduy M; Sáez Rodríguez M; Noda Cabrera A
Br J Dermatol; 2009 Feb; 160(2):409-14. PubMed ID: 19016706
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of a combined 308-nm excimer lamp and topical mid-potent steroid treatment for facial vitiligo: a preliminary, randomized double-blinded controlled study.
Juntongjin P; Toncharoenphong N
Lasers Med Sci; 2020 Dec; 35(9):2023-2029. PubMed ID: 32458080
[TBL] [Abstract][Full Text] [Related]
30. Integrating neuronal involvement into the immune and genetic paradigm of vitiligo.
Al Abadie MS; Gawkrodger DJ
Clin Exp Dermatol; 2021 Jun; 46(4):646-650. PubMed ID: 33098692
[TBL] [Abstract][Full Text] [Related]
31. Remission of Severe Eyelid Dermatitis With a Topical Janus Kinase Inhibitor.
Peterson D; King B
Dermatitis; 2021 Oct; 32(1S):e98-e99. PubMed ID: 34405834
[No Abstract] [Full Text] [Related]
32. Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo.
Hwang JR; Driscoll MS
Ann Pharmacother; 2023 Aug; 57(8):948-955. PubMed ID: 36564903
[TBL] [Abstract][Full Text] [Related]
33. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
Liu LY; King BA
J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S18-S20. PubMed ID: 29273099
[TBL] [Abstract][Full Text] [Related]
34. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
[TBL] [Abstract][Full Text] [Related]
35. Vitiligo: an update on systemic treatments.
Searle T; Al-Niaimi F; Ali FR
Clin Exp Dermatol; 2021 Mar; 46(2):248-258. PubMed ID: 33350506
[TBL] [Abstract][Full Text] [Related]
36. How suitable are JAK inhibitors in treating the inflammatory component in patients with alopecia areata and vitiligo?
Moya EC; Bruinsma RL; Kelly KA; Feldman SR
Expert Rev Clin Immunol; 2022 Mar; 18(3):189-191. PubMed ID: 35107044
[No Abstract] [Full Text] [Related]
37. Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
Niu C; Xie H; Aisa HA
Mini Rev Med Chem; 2021; 21(20):3203-3218. PubMed ID: 33823765
[TBL] [Abstract][Full Text] [Related]
38. Topical immunomodulators are effective for treatment of vitiligo.
Choi CW; Chang SE; Bak H; Choi JH; Park HS; Huh CH; Kim CW; Kim SE; Mun SK; Kim BJ; Kim MN
J Dermatol; 2008 Aug; 35(8):503-7. PubMed ID: 18789070
[TBL] [Abstract][Full Text] [Related]
39. The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: study protocol for a randomized controlled trial.
Niezgoda A; Winnicki A; Kosmalski T; Kowaliszyn B; Krysiński J; Czajkowski R
Trials; 2019 Jan; 20(1):78. PubMed ID: 30683146
[TBL] [Abstract][Full Text] [Related]
40. Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mouse model of rhododendrol-induced vitiligo.
Hayashi M; Okamura K; Abe Y; Hozumi Y; Suzuki T
J Dermatol; 2019 Jun; 46(6):548-550. PubMed ID: 30969438
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
